This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Aklilu, F. Articles by Rabbani, S. A. Search for Related Content PubMed PubMed Citation Articles by Aklilu, F. Articles by Rabbani, S. A.

Induction of Parathyroid Hormone-related Peptide by the Ras Oncogene: Role of Ras Farnesylation Inhibitors as Potential Therapeutic Agents for Hypercalcemia of Malignancy¹

Department of Medicine, McGill University and Calcium Research Laboratory and Molecular Oncology Group, Royal Victoria Hospital, Montreal, Quebec, H3A 1A1 Canada

Parathyroid hormone related peptide (PTHRP) is the major causal agent in the syndrome of malignancy-associated hypercalcemia (MAH). Several studies have shown that PTHRP production is increased in response to growth factors and oncogenes, such as Tpr-Met, that are associated with the tyrosine kinase signaling pathway. Using site-directed mutagenesis of Tpr-Met and chemical inhibitors of phosphotidylinositol-3 kinase and Ras isoprenylation, we demonstrated previously that induction of PTHRP is mediated via the Ras signaling pathway. In the present study, we have directly investigated the role of the Ras oncogene in MAH. As a model system, we used Fisher rat 3T3 fibroblasts stably transfected with a Ras oncogene (Ras-3T3). Ras transfection enhanced PTHRP production 5–10-fold in these cells, and inoculation of this cell line into nude mice led to the development of hypercalcemia within 2 weeks. We used this system to evaluate the effect of a potent inhibitor of Ras processing, B-1086, on cell growth, PTHRP production, plasma calcium, and tumor growth. Treatment of Ras-3T3 cells in vitro with B-1086 at 0.1–10 µg/ml produced a significant reduction in PTHRP mRNA expression and PTHRP secretion and a significant decrease in cell proliferation. Treatment in vivo of BALB/c/nu/nu mice bearing Ras-3T3 tumors with B-1086 resulted in a significant inhibition in tumor growth. In addition, this treatment produced near normalization of serum Ca²⁺, a significant decrease in plasma PTHRP, and a reduction in tumoral PTHRP mRNA levels. These results show that the Ras pathway is involved in PTHRP production by tumors, identifies Ras as a potential target for treatment of MAH, and demonstrates Ras processing inhibitors as candidate therapeutic agents against this syndrome.

¹ This work was supported by Medical Research Council of Canada Grants MT-10630, MT-12609, and MT-5775 and by a grant from the National Cancer Institute of Canada.

² To whom requests for reprints should be addressed, at Calcium Research Laboratory, Room H4-72, Royal Victoria Hospital, 687 Pine Avenue West, Montreal, Quebec, H3A, 1A1 Canada. Phone: (514) 843-1632; Fax: (514) 843-1712.

Received 5/29/97. Accepted 8/18/97.

This article has been cited by other articles:

				H. Jallal, M.-L. Valentino, G. Chen, F. Boschelli, S. Ali, and S. A. Rabbani A Src/Abl Kinase Inhibitor, SKI-606, Blocks Breast Cancer Invasion, Growth, and Metastasis In vitro and In vivo Cancer Res., February 15, 2007; 67(4): 1580 - 1588. [Abstract] [Full Text] [PDF]

				R. Linforth, N. Anderson, R. Hoey, T. Nolan, S. Downey, G. Brady, L. Ashcroft, and N. Bundred Coexpression of Parathyroid Hormone Related Protein and Its Receptor in Early Breast Cancer Predicts Poor Patient Survival Clin. Cancer Res., October 1, 2002; 8(10): 3172 - 3177. [Abstract] [Full Text] [PDF]

				R. K. Lindemann, P. Ballschmieter, A. Nordheim, and J. Dittmer Transforming Growth Factor beta Regulates Parathyroid Hormone-related Protein Expression in MDA-MB-231 Breast Cancer Cells through a Novel Smad/Ets Synergism J. Biol. Chem., November 30, 2001; 276(49): 46661 - 46670. [Abstract] [Full Text] [PDF]

				F. Aklilu, J. Gladu, D. Goltzman, and S. A. Rabbani Role of Mitogen-activated Protein Kinases in the Induction of Parathyroid Hormone-related Peptide Cancer Res., March 1, 2000; 60(6): 1753 - 1760. [Abstract] [Full Text]